Hexane

Hexane

SCHEMBL3504297

CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCCCCC.CCO.CCO.CCO.CCO.CCO.CCO.CCO.CCO.CCO.CCO.CCO.CCO.CCO.CCO.CCO

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hexane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.69
TSHR P16473 5/20 0.64
LMNA P02545 4/20 0.64
ALDH1A1 P00352 4/20 0.64
HSD17B10 Q99714 1/20 0.64
MEN1 O00255 1/20 0.64
KMT2A Q03164 1/20 0.64
THRB P10828 1/20 0.64
CES2 O00748 4/20 0.47
CES1 P23141 4/20 0.47
SLC22A1 O15245 2/20 0.47
SLC22A2 O15244 1/20 0.47
AKR1B1 P15121 1/20 0.44
DNM1 Q05193 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hexane SCHEMBL2338690 1.00 SMN1; SMN2 (0.69) SMN1; SMN2TSHRLMNAALDH1A1HSD17B10
Hexane SCHEMBL8823 1.00
Hexane SCHEMBL378683 1.00 SMN1; SMN2 (0.69) SMN1; SMN2TSHRLMNAALDH1A1HSD17B10
Hexane SCHEMBL378546 1.00 SMN1; SMN2 (0.69) SMN1; SMN2TSHRLMNAALDH1A1HSD17B10
Hexane SCHEMBL18921395 1.00 SMN1; SMN2 (0.69) SMN1; SMN2TSHRLMNAALDH1A1HSD17B10
Hexane SCHEMBL18920351 1.00 SMN1; SMN2 (0.69) SMN1; SMN2TSHRLMNAALDH1A1HSD17B10
Hexane SCHEMBL7802385 1.00 SMN1; SMN2 (0.69) SMN1; SMN2TSHRLMNAALDH1A1HSD17B10
Hexane SCHEMBL3826930 1.00 SMN1; SMN2 (0.69) SMN1; SMN2TSHRLMNAALDH1A1HSD17B10
Hexane SCHEMBL5014044 1.00 SMN1; SMN2 (0.69) SMN1; SMN2TSHRLMNAALDH1A1HSD17B10
Hexane SCHEMBL5012800 1.00 SMN1; SMN2 (0.69) SMN1; SMN2TSHRLMNAALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190788-A1 Amide derivatives as kinase inhitors DEVGEN N.V. (BE) 2010-07-29 US disclosed
EP-1462444-B1 INTERMEDIATE FOR BIOTIN AND PROCESS FOR PRODUCING THE SAME MITSUBISHI TANABE PHARMA CORP (JP) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190788-A1 Amide derivatives as kinase inhitors MAP3K1, MAPK1, MAP3K21 SMN1; SMN2 3251/4885TSHR 1576/4885LMNA 762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.